A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment
Authors:
- Teresa Gómez-IslaTGTeresa Gómez-Isla
- Rafael BlesaRBRafael Blesa
- Merce BoadaMBMerce Boada
- Jordi ClarimónJCJordi Clarimón
- Teodoro Del SerTSTeodoro Del Ser
- Gemma DomenechGDGemma Domenech
- Jose M. FerroJFJose M. Ferro
- Beatriz Gómez-AnsónBGBeatriz Gómez-Ansón
- Jose M. ManubensJMJose M. Manubens
- Jose M. Martínez-LageJMJose M. Martínez-Lage
- David MuñozDMDavid Muñoz
- Jordi Peña-CasanovaJPJordi Peña-Casanova
- 1 January 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 22 (1) , 21-29
Abstract
Amnestic mild cognitive impairment represents, in many cases, the earliest clinical phases of Alzheimer disease. Anti-inflammatory agents have epidemiologic support as drugs potentially beneficial in Alzheimer disease. In vivo studies have shown that Triflusal and its active metabolite 2-hydroxy-4-trifluoromethyl-benzoic acid have potent anti-inflammatory actions in the central nervous system. We conducted a randomized, double-blind, placebo-controlled trial of Triflusal in patients with amnestic mild cognitive impairment. Subjects were randomly assigned to receive 900 mg of Triflusal or placebo for 18 months. The primary outcome was a change in Cognitive subscale of the Alzheimer Disease Assessment Scale; conversion to dementia was a secondary outcome. A slow rate of recruitment forced a premature cessation of the study. Two hundred and fifty-seven subjects were enrolled and followed-up for an average of 13 months. The significance level was not reached for the primary outcome even though a trend in favor of Triflusal was observed. However, there was a significant difference in the probability of progression to dementia of Alzheimer's type with a lower risk in the Triflusal compared with the placebo group (hazard ratio, 2.10; 95% confidence interval, 1.10-4.01; P=0.024). In this study, Triflusal therapy was associated with a significant lower rate of conversion to dementia that is likely to be clinically relevant. Because the trial was prematurely halted, these results should be interpreted with caution and require further confirmation.Keywords
This publication has 29 references indexed in Scilit:
- Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseasesCellular and Molecular Life Sciences, 2007
- Neuropathologic Features of Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2006
- Triflusal for preventing serious vascular events in people at high riskCochrane Database of Systematic Reviews, 2005
- A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive ImpairmentNeuropsychopharmacology, 2005
- A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activityNature, 2001
- Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) [RETIRED]Neurology, 2001
- Oral administration of the anti-inflammatory substance triflusal results in the downregulation of constitutive transcription factor NF-κB in the postnatal rat brainNeuroscience Letters, 2000
- Mild Cognitive ImpairmentArchives of Neurology, 1999
- 4‐trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2‐hydroxy‐4‐trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor κB activationBritish Journal of Pharmacology, 1999
- Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's diseaseNeurology, 1996